Duchenne

The "miracle drug" that could save the lives and well-being for hundreds of people may have just received some great news. Dr. Ron Farkas has left the U.S. Food & Drug Administration, people familiar with the matter told Benzinga. Why would his departure raise hope for the "...

It’s been a wild ride so far this year for shareholders of Sarepta Therapeutics Inc (NASDAQ: SRPT). The year got off to a disastrous start back in January when the stock plummeted 55 percent in a single trading day after the FDA released advisory committee briefing documents that were highly...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) gained more than 30 percent Friday morning, while shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) lost more than 6 percent. The Wall Street Journal reported that BioMarin faces an FDA advisory committee next week to vote for approval or...